RTX pursues its product discovery work primarily utilizing classic rational-based medicinal chemistry approaches, supported by computational algorithms based upon crystallographic data. The Company operates an efficient in-house iterative drug discovery process, whereby hits are subjected to rapid validation by in vitro cell culture testing with quick follow-on in vivo confirmation in rodent and large animal disease models. This approach has consistently yielded highly potent and innovative pharmaceutical candidates. In our previous firm, this strategy yielded multiple clinical candidates, one of which resulted in a major oncology partnership with large pharma and a second molecule that has advanced through late Phase 2 clinical trials with an impressive demonstration of clinical efficacy in the ophthalmic space.

The Company tackles biological problems of high fundamental interest common to disease pathogenesis, rather than focusing on a particular therapeutic area. This approach consistently produces novel chemistry that has broad applicability across disease states that share common underlying mechanisms of injury.